Background This analysis aimed to evaluate the clinical impact of high bleeding risk (HBR)
on adverse events after percutaneous coronary intervention (PCI). Methods We …

Previously we briefly reported the effect of 1-month dual antiplatelet therapy (DAPT) for
patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in …

Objectives To explore the impact of 6‐versus 12‐month dual antiplatelet therapy (DAPT) on
the clinical prognosis of high bleeding risk (HBR) patients. Background The optimal DAPT …

Introduction Patients at high bleeding risk (HBR patients) represent an important subset of
patients undergoing percutaneous coronary intervention (PCI). It remains unclear whether a …

Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy
(DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary …

Introduction: Patients at high bleeding risk (HBR patients) represent an important subset of
patients undergoing percutaneous coronary intervention (PCI). It remains unclear whether a …

Background High bleeding risk (HBR) patients represent nearly one-half of percutaneous
coronary intervention patients. The EVOLVE Short DAPT study demonstrated favorable …

The EVOLVE Short DAPT study demonstrated the safety of truncated dual antiplatelet
therapy (DAPT) in patients with a high bleeding risk (HBR) treated with SYNERGY stent …

Background: Dual antiplatelet therapy (DAPT) helps prevent ischemic events after coronary
stenting but comes with an increased risk of bleeding. Several risk scores have been …

Background: To date, it has not been ascertained whether shortening the duration of dual
antiplatelet therapy (DAPT) can benefit high bleeding risk (HBR) patients. This systematic …